Alterity Therapeutics Limited
PRNAF
$0.40
$0.0514.29%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | 0.40% | -69.92% | |||
| Total Revenue | 0.40% | -69.92% | |||
| Cost of Revenue | 0.53% | 73.46% | |||
| Gross Profit | 0.41% | -75.16% | |||
| SG&A Expenses | 0.39% | 10.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.63% | -49.52% | |||
| Total Operating Expenses | 0.39% | 21.96% | |||
| Operating Income | -0.39% | -46.62% | |||
| Income Before Tax | -0.39% | -50.28% | |||
| Income Tax Expenses | 0.56% | -11.88% | |||
| Earnings from Continuing Operations | -0.39% | -49.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.39% | -49.88% | |||
| EBIT | -0.39% | -46.62% | |||
| EBITDA | -0.39% | -46.64% | |||
| EPS Basic | 0.00% | -40.65% | |||
| Normalized Basic EPS | -0.74% | -40.63% | |||
| EPS Diluted | -0.44% | -45.16% | |||
| Normalized Diluted EPS | -0.74% | -40.63% | |||
| Average Basic Shares Outstanding | 0.00% | 6.78% | |||
| Average Diluted Shares Outstanding | 0.00% | 6.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||